What Are the Key Factors That Make a Clinical Evaluation MDR-Ready?
- chris464049
- Apr 23
- 3 min read
Updated: Apr 27
By Hands-on Research – MDR Clinical Evidence Strategists
MDR Clinical Evaluation Requirements
If you’re a small or mid-sized medical device manufacturer, you already know this:
The EU MDR clinical evaluation requirements haven’t just raised the bar - they’ve changed expectations entirely.
They are structured, predictable, and far less tolerant of weak justifications and evidence.
At Hands-on Research, we work with manufacturers navigating:
Limited internal clinical expertise
Poorly maintained legacy documentation under MDD
Budget and resource constraints
Increasing Notified Body scrutiny
The Result: Many Clinical Evaluation Reports (CERs) are complete, but not MDR-ready.
What Is an MDR-Ready Clinical Evaluation Report?
An MDR-ready clinical evaluation is not just a check box exercise.
It is a defensible and compliant report that demonstrates:
Sufficient clinical evidence (Article 61, Annex XIV) or justification for the use of technical evidence (Article 61(10))
Measurable Safety and Performance objectives and acceptance criteria
A clear benefit-risk profile
Analysis of risk management and Post Market Surveillance data
Ongoing evaluation of clinical safety and performance
As further reinforced in MDCG 2020-13 (Clinical Evaluation Assessment Report Template), Notified Bodies are expected to critically assess not just the presence of clinical data, but the quality of clinical reasoning, justification of evidence, and overall consistency of the clinical evaluation.
Why Many CERs Fail Under MDR Review
One of the most common non-conformities we see:
Manufacturers focus on updating the CER - rather than strengthening the clinical strategy.
Typical weaknesses include:
Over-reliance on literature without justification
Weak or unsupported equivalence claims
Inconsistencies with Technical Documents
Unsupported clinical claims
Confused Intended Purposes and Indications
Misalignment between CER, risk file, and IFU
Under MDR - and aligned with expectations reflected in MDCG 2020-13 - these gaps lead to:
Additional review cycles
Major nonconformities
Delays to certification
Key Elements of an MDR-Ready Clinical Evaluation
1. A Clearly Defined Clinical Evidence Strategy
An MDR-compliant CER starts with strategy - not writing.
You need to clearly define:
Intended purpose and clinical claims
Device risks and residual uncertainty
Evidence required to demonstrate safety and performance
How evidence will evolve across the lifecycle
Without this, your clinical evaluation becomes reactive.
2. Sufficient Clinical Evidence: Proportionate to Risk
A core MDR requirement is demonstrating sufficient clinical evidence. But sufficiency is not about volume.
It is about whether your data is:
Relevant to your device and claims
Proportionate to device risk class
Adequate to reduce uncertainty
In line with MDCG expectations, reviewers increasingly assess how well evidence is justified - not just how much exists.
3. MDR Equivalence Requirements: What Still Matters
Equivalence under MDR remains one of the most scrutinised areas.
To demonstrate equivalence, manufacturers must show:
Technical equivalence
Biological equivalence
Clinical equivalence
Availability to data on the equivalent device
MDCG 2020-5 provides guidance on how to appropriately demonstrate equivalence to align with the requirements of the MDR. Notified Bodies will scrutinised equivalence tables if equivalence has been claimed.
4. Post-Market Clinical Follow-Up (PMCF) Under MDR
Whilst a PMCF Plan should be a separate standalone document to the clinical evaluation, PMCF data is a crucial input to clinical evaluation.
An MDR-ready PMCF plan must:
Address residual clinical uncertainty
Be linked to risks and claims
Include measurable endpoints
Be integrated with PMS
Notified Body expectations, reflected in MDCG review approaches, require PMCF to be purpose-driven, not generic.
5. Alignment Across Technical Documentation
An MDR clinical evaluation cannot stand alone.
It must align with:
Risk Management File
Instructions for Use (IFU)
PMS and PMCF data
Summary of Safety and Clinical Performance (SSCP) where appropriate
How to Prepare for MDR Notified Body Scrutiny
To ensure your clinical evaluation is MDR-ready:
Define your clinical strategy route to conformity early
Identify how you meet relevant General Safety and Performance Requirements
Identify and address uncertainty proactively
Ensure evidence is proportionate to risk
Strengthen justifications—not just data volume
Align all technical documentation
Conclusion: Building a Defensible MDR Clinical Evaluation
An MDR-ready Clinical Evaluation is not about producing more documentation. It’s about:
Clear clinical reasoning
Proportionate and justified evidence
Transparent handling of uncertainty
Strong alignment across your technical file
Because ultimately, the question is:
“Will your clinical evidence withstand Notified Body scrutiny?”
If that answer isn’t certain, that’s where we can help.
Get clear, expert insight into your medical device regulatory strategy in a no-strings-attached 30-minute call with one of our experts. Whether you’re preparing for EU MDR, UKCA, or global submission, this session will quickly highlight where you stand—and where you can strengthen your approach.
In this call, you will:
Uncover weaknesses in your clinical and regulatory documentation
Spot risks that could delay approval or raise questions during review
Get clarity on classification, routes to market, and compliance strategy
Understand how ready you are for audit or Notified Body scrutiny
Leave with practical, prioritised next steps
No pressure. Just straightforward, high-value guidance to help you move faster and with confidence.
Comments